Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Tekmira Pharmaceuticals
Tekmira Pharmaceuticals
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Tekmira to suspend Ebola drug development
Will change name to Arbutus Biopharma and focus on developing treatments for hepatitis B
Research & Development
Tekmira Pharmaceuticals in multiyear agreement with Bristol-Myers Squibb
Transaction includes US$3m upfront payment to Tekmira
Research & Development
A silent revolution
Increased understanding of RNA interference has led to an explosion of gene silencing drug research projects. Dr Sarah Houlton reviews the progress being made in recent drug trials and looks at the remaining challenges
Research & Development
Tekmira and Pfizer agree research collaboration
They will evaluate SNALP technology to deliver small interfering RNA (siRNA) molecules
Subscribe now